Lead Beneficiary: SCIENSANO (Belgium)
Hélène Antoine-Poirel
Participants:
High contribution: SCIENSANO, UNICANCER, IBB, ACC, FICAN, NHRF, CUSL, VIB, UGent, DKFZ, ACC, FPG, I3S, IDIVAL, CNIO, KI, RM, UKW, CRO AVIANO, LSMUL KK, AOUPR, UNIMI, ISNB, IOCN
Low contribution: INC, BS, KUL, IJB, UZA, FHF, UNITO, SAS, CSGVA, SCCC, OOI, HUB, LNS, LIH, FPG, IOV, MUW,
Objectives
The NoE on omics will provide services on comprehensive guidance and recommendations to address challenges related to the implementation of omics in clinical practice, by catalysing a community, building, training, and transferring learning between mature and emerging technologies. The organisational structure of this initiative is centred around headquarters, acting as the hub for core facilities that support crosscutting tasks across the four priority domains defined basing on clinical readiness. The EU NoE on Omics will be composed of EU expert partners in the different domains and services and will rely on national/regional networks. Pluriannual consultations of experts for the 4 identified domains will be organised to identify unmet needs and to prioritize the activities that must be addressed by the cross-cutting tasks. The partners from each member state will be responsible for cascading these resources nationally. The measurement of large-scale non-biological phenomena is not included in this NoE on Omics, however integration of radiomics (WP10) aspects will be considered in collaboration with this WP.
The four priority domains are as follows:
- Established omics in the standard of care – the domain emphasizes the need for a homogeneous and widespread implementation of omics technologies with high quality and equality across EU MS (domain lead: FPG)
- Omics in clinical research – this domain focuses on demonstrating the added value of omics technologies for specific indications via use cases identified in WP5 and via other NoEs or ERNs (domain lead: UNICANCER-IC)
- Omics in translational research – this domain seeks to facilitate the validation pathway and provides access to high-potential omics technologies that are far beyond the clinical application (domain lead: I3S)
- Integrated Omics – innovative IT tools (machine learning / Artificial Intelligence) to foster the use of multi-omics in clinical research and ultimately clinical practice. (domain lead: KI)
These four priority domains are supported by four cross cutting tasks in close interaction with WP5-11:
- Omics technical and clinical support from research setting to standard of care implementation
- Legal and ethical aspects
- Training Centre
- Stimulating synergies, collaborations and looking for funding opportunities to ensure sustainability
Tasks
T9.1 NoE governance, sustainability, dissemination (Task leader: SCIENSANO)
T9.2 Omics technical & clinical support (Task leader: UNICANCER)
T9.3 Legal & Ethical aspects (Task leader: SCIENSANO)
T9.4 Training Center (Task leader: IBB)
T9.5 Synergies, collaborations, funding opportunities (Task leader: ACC)
